Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

APLS Apellis Pharmaceuticals Inc

32,10

0,19 (0,60%)

Última atualização: 12:18:14

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.

Date of Notice

12/23/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Emily Navaro, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jeffrey Eisele.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Apellis Pharmaceuticals (NASDAQ:APLS)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos Apellis Pharmaceuticals.

Apellis Pharmaceuticals (NASDAQ:APLS)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos Apellis Pharmaceuticals.

Notícias Apellis Pharmaceuticals Inc

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 27 de Dezembro de 2024 (6 dias atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Segunda, 23 de Dezembro de 2024 (1 semana atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 13 de Dezembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Quarta, 11 de Dezembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sexta, 6 de Dezembro de 2024 (4 semanas atrás) • GlobeNewswire Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Quarta, 27 de Novembro de 2024 (1 mês atrás) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Sexta, 22 de Novembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Terça, 12 de Novembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Sexta, 8 de Novembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Terça, 5 de Novembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Terça, 5 de Novembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

U.S. Index Futures Rise as Election Looms; Oil and Gold Prices Steady
Terça, 5 de Novembro de 2024 (2 meses atrás) • IH Market News

Mais Notícias de Apellis Pharmaceuticals Inc

Índice Bovespa

Fictor Alimentos ON

PÃO DE AÇUCAR ON

Automob Participacoes ON

$Logo da Infracommerce Caxaas ON (IFCM3).$

Infracommerce Caxaas ON

Fundo Invest Amazonia Fi...

FER HERINGER ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições